E
COMPANY PROFILE
Epizyme
Epizyme - Personalized Therapeutics & The Power of Epigenetics
Valuation
$249M
Market cap · 2026
Revenue
$74M
Latest reported FY
At a glance
- Status
- Listed
- Founded
- 2007
- Headquarters
- Cambridge, United States
- Listing
- IPO 2013
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- MBMPM BioImpact
- TSThe Leukemia & Lymphoma Society
- GSGSK
Kleiner Perkins
Series B and later5 investors entered at this stage
- RPRoyalty Pharma
- BMBaylor College of Medicine
- AVAmgen Ventures
- BCBay City Capital
NEA
Founders
Hidden — book a demo/100
quality score
Key operators
Hidden — book a demo
quality score
Potential founders
Hidden — book a demo
likely future founders
Talent movements
Hidden — book a demo in · Hidden — book a demo out
past 12 months
Source: Dealroom Talent Intelligence.
Alumni founders
Former Epizyme employees who went on to found companies, sorted by Dealroom signal score.
VTVesigen TherapeuticsEst. 2019
Robert MillmanUnited StatesSignal score69
RURulaiEst. 2016YZYi ZhangUnited States
Signal score69
ATAccent TherapeuticsEst. 2017
Robert A. CopelandUnited StatesSignal score68
MMMenlo MicroEst. 2016RSRisa StackUnited States
Signal score65
GOGritstone OncologyEst. 2015
Andrew AllenUnited StatesSignal score65
2 more alumni-founded companies in this previewBook a demo
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Epizyme on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Epizyme on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.